Published
5 minute read
When someone has her first urinary tract infection, treating the infection is usually the obvious priority.
When she is sitting in front of me after her sixth, the question needs to become bigger.
I want to know which organisms grew on the cultures. Did they recur or change? Do the infections cluster around sex? Has anything changed with bowel function? Are there vaginal symptoms? Is she emptying her bladder properly? What is happening hormonally? And what does the examination tell us?
At that point, I am not interested only in which antibiotic treated the last infection.
I want to understand why the urinary tract has become vulnerable to the next one.
Medicine organizes the body into specialties.
The bladder goes to urology. The vagina goes to gynecology. The bowel goes somewhere else.
Bacteria are less interested in those boundaries.
Many UTIs are caused by organisms such as E. coli that normally live in the gastrointestinal tract. The rectum, vaginal environment, urethra and bladder also sit anatomically close together.
Increasingly, research is examining recurrent UTI as an interaction among those environments rather than as a series of isolated bladder infections.
A 2026 U.S. study compared 31 postmenopausal women with recurrent UTIs with 31 women without them. Researchers examined the vaginal microbiome, urinary pathogens and antimicrobial-resistance markers, as well as rectal bacteria.
Women with recurrent UTIs showed different vaginal microbial patterns, more Gram-negative urinary pathogens and more antimicrobial-resistance markers. Investigators also identified overlapping organisms between rectal and urogenital sites, supporting the possibility that the gastrointestinal tract can act as a reservoir for bacteria that later reach the urinary tract.
The study was small and cross-sectional, so it cannot tell us that one microbial pattern directly produced the infections.
But it does not stand alone. Earlier research has also linked recurrent UTI, estrogen status and the postmenopausal urogenital microbiome.
The model is becoming more complex for a reason.
The term genitourinary syndrome of menopause, or GSM, was adopted because “vulvo-vaginal atrophy” did not adequately describe what clinicians were seeing and was frankly an insulting title to give your vagina. Furthermore, GSM is a progressive condition, unlike hot flashes which last on average 7 - 10 years before stopping, GSM will continue and often worsens over time.
Declining estrogen affects tissues around the vulva, vagina, urethra and bladder. Vaginal pH can rise. Lactobacillus populations can change. Tissue can become thinner and more vulnerable to irritation and injury (think microtears). .
Some women notice dryness.
Some notice pain with sex.
Some notice urinary urgency or burning.
And some begin having UTIs after years without them.
That is why recurrent urinary infections after menopause deserve a hormonal conversation as well as an infectious-disease conversation.
Vaginal estrogen is a guideline-supported preventive option for recurrent UTIs in peri- and postmenopausal women.
Evidence goes back decades. A randomized trial published in the New England Journal of Medicine in 1993 demonstrated fewer recurrent UTIs among postmenopausal women treated with intravaginal estriol. Subsequent reviews reached similar conclusions, and vaginal estrogen is now recommended in the joint American and Canadian urology guideline for recurrent UTI.
Systemic oral or transdermal estrogen has not demonstrated the same UTI-prevention effect.
In Canada, prevention of recurrent UTI is generally considered a guideline-supported but off-label use of vaginal estrogen. That is not unusual in medicine, but it is worth explaining clearly rather than presenting the treatment as though it were specifically licensed for that indication.
When someone has a symptomatic bacterial urinary tract infection, antibiotics are often needed to clear the infection.
The goal of antibiotic stewardship is not to make patients endure infections without treatment.
The goal is to use antibiotics when they are treating an infection, and to stop using them as a substitute for understanding why infections are recurring.
This is particularly important because repeated antibiotic exposure can select for resistant organisms.
It is also why a positive urine test without urinary symptoms is a different situation. Canadian stewardship recommendations generally advise against treating asymptomatic bacteriuria with antibiotics in nonpregnant adults unless there is another specific indication.
More antibiotics are not automatically more prevention.
This is one of the most useful distinctions we can make.
Burning with urination may be a UTI.
It may also occur with GSM, pelvic-floor dysfunction, vulvar conditions, vaginal infections, bladder pain syndromes or other contributors.
Urgency and frequency are equally nonspecific.
If someone repeatedly has “UTI symptoms” but cultures keep coming back negative, I do not consider that an irrelevant detail.
It is part of the diagnosis.
Sorting that out is a clinical decision, not a symptom checklist.
Recurrent UTI is a good example of why women’s health works poorly when we look at one organ at a time.
The bladder may be where the infection appears, but the biological environment around that bladder includes hormones, vaginal tissue, the pelvic floor, bowel function, microbial communities and behaviour.
We are still learning how those pieces interact.
That uncertainty should not stop us from treating what we already understand.
It should make us more curious about the woman sitting in front of us after UTI number six.
Because common is not inevitable.
And the goal should not simply be to treat her seventh.
This article is general information, not a substitute for a clinical assessment
written by
Dr. Alaina Garbens is a physician specializing in women's health, with expertise in urology, pelvic health, and hormonal changes throughout life. She takes a personalized, evidence-informed approach to helping women navigate their health and wellness needs.
